Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
-0.12 (-1.40%)
Delayed:   2:34PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 8.37 - 8.72
52 week 2.23 - 14.17
Open 8.53
Vol / Avg. 48,200.00/50,831.00
Mkt cap 702.07M
P/E     -
Div/yield     -
EPS -1.80
Shares 83.43M
Beta 3.23
Inst. own     -
Aug 3, 2017
Q2 2017 Aurinia Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 15, 2017
Q1 2017 Aurinia Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -167551.60% -13465.32%
Operating margin -35758.07% -13187.28%
EBITD margin - -12332.37%
Return on average assets -150.59% -51.44%
Return on average equity -199.73% -83.33%
Employees 20 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board, Chief Executive Officer
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Celia Economides Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
George M. Milne Jr., Ph.D. Director
Age: 73
Lorin Jeffry Randall Director
Benjamin Rovinski Ph.D. Independent Director
Age: 58